Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.50    0.00 (0.00%)
Bid:
2.50
Ask:
2.80
Spread: 0.30 (12.00%)
Market Cap: £4.56m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Directorate Changes

30 Jul 2018 07:00

RNS Number : 0813W
Nanoco Group PLC
30 July 2018
 

30 July 2018

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

Directorate Changes

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, today announces that, as part of a structured reorganisation of the Company's executive team following Keith Wiggins resignation as Chief Operating Officer in June, Nanoco will combine its Chief Financial Officer and Chief Operating Officer positions into one unified role.

 

The Board is pleased to announce that Brian Tenner has been appointed to this new combined role, effective from 20 August 2018. Brian is currently Chief Financial Officer of NCC Group plc ("NCC"), a leading pure play cyber security advisory business. On the 20 June 2018 it was announced that Brian would leave NCC in August 2018. Previously he was Group Finance Director and a member of the Board at Renold Plc (2010-2016), Scapa Group Plc (2007-2010) and BNFL Plc - British Nuclear Group (2003-2007).

 

As a result of the reorganisation, David Blain will stand down from his position as Chief Financial Officer on the 20 August 2018. David will remain with Nanoco until 15 October 2018 to facilitate an orderly handover of his duties.

 

There is no further information to be disclosed relating to Brian under paragraph 9.6.13 of the UK Listing Authority Listing Rules.

 

Michael Edelman, Chief Executive of Nanoco, said:

 

"On behalf of the whole team, I would like to thank David for the very significant contribution he has made to Nanoco as our Chief Financial Officer over the past three years. He has been a key part of the team as we have driven our commercialisation strategy and maintained robust financing and tight control over costs. We wish him well for all his future endeavours.

 

"I would like to welcome Brian to the team in this newly created role. His extensive experience will be invaluable to our Executive Team and the Board as Nanoco continues to gain commercial momentum."

 

- Ends -

 

 

For further information, please contact:

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

 

Chris Richards, Non-Executive Chairman

 

Caroline Watson, Investor Relations Manager

Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

 

 

 

 

MHP Communications

Tel: +44 (0) 20 3128 8570

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com

 

 

The information contained within this announcement constitutes inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-technology to create a brighter, more sustainable future. Based on breakthrough science, Nanoco's proprietary manufacturing process enables the large-scale production of its cadmium-free CFQD® quantum dots for multiple applications including LCD display, lighting, healthcare, nano-materials and solar.

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAZVLFLVDFBBBE
Date   Source Headline
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding
16th Aug 20227:00 amRNSTrading Update
28th Jul 202210:42 amRNSHolding(s) in Company
13th Jul 20222:03 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
13th Jul 202212:00 pmRNSDirector/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
29th Jun 20227:00 amRNSChange of Auditor
23rd Jun 20223:48 pmRNSDirector/PDMR Shareholding
22nd Jun 20222:25 pmRNSHolding(s) in Company
21st Jun 20223:36 pmRNSDirector/PDMR Shareholding
21st Jun 20229:06 amRNSReplacement: Director/PDMR Shareholding
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 20224:36 pmRNSPrice Monitoring Extension
17th Jun 202210:45 amRNSHolding(s) in Company
14th Jun 20229:42 amRNSHolding(s) in Company
9th Jun 20227:00 amRNSBlock listing Six-monthly Return
8th Jun 202212:00 pmRNSResults of Fundraise
8th Jun 20227:00 amRNSFundraise significantly over-subscribed
7th Jun 20225:16 pmRNSReplacement: Litigation Update
7th Jun 20224:55 pmRNSLitigation Update
6th Jun 20227:02 amRNSTrading Update & Proposed Fundraise
6th Jun 20227:00 amRNSMajor Work Package for European Customer
23rd May 20225:00 pmRNSHolding(s) in Company
17th May 20227:02 amRNSLitigation Update
13th May 202212:15 pmRNSHolding(s) in Company
13th Apr 20222:49 pmRNSHolding(s) in Company
12th Apr 20227:00 amRNSInterim Results
17th Mar 20227:00 amRNSAdditional Work Package for European Customer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.